Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Non-Hodgkin × Crizotinib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 12 Multiple Myeloma 4 Lymphoma 3 Lung Neoplasms 3 Hematologic Neoplasms 2 Uveal Melanoma 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Endocrine Neoplasia Type 2a 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large-Cell, Anaplastic 1 Granuloma, Plasma Cell 1 Endometrial Cancer Recurrent 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1 Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1 Adenocarcinoma 1

Interventions

Cyclophosphamide 58 Rituximab 47 fludarabine 38 fludarabine phosphate 25 obinutuzumab 17 venetoclax 16 Lenalidomide 16 ibrutinib 15 Etoposide 14 Prednisone 13 pirtobrutinib 12 Whole-Body Irradiation 12 Mycophenolic Acid 11 Melphalan 11 Bendamustine Hydrochloride 11 Tacrolimus 10 Specimen Handling 10 Filgrastim 10 Doxorubicin 10 Biopsy 10 Vincristine 9 Magnetic Resonance Spectroscopy 9 Granulocyte Colony-Stimulating Factor 9 pembrolizumab 8 Stem Cell Transplantation 8 Peripheral Blood Stem Cell Transplantation 8 Nivolumab 8 Gemcitabine 8 Cytarabine 8 tocilizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03297606 2026-03-04

CAPTUR

Canadian Cancer Trials Group

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡